Nasopharyngeal carcinoma (NPC) is a highly invasive and metastatic cancer that is widely prevalent in southern China. To date, three major etiologic factors, genetic susceptibility, endemic environmental factors, and Epstein--Barr virus (EBV) infection, are believed to induce NPC[@b1]. Due to its sensitivity to both chemotherapy and radiotherapy, NPC can be successfully treated if the tumor is locally confined to the nasopharynx at diagnosis. Unfortunately, many NPC patients are usually diagnosed at advanced stages. Partially distant metastases and recurrence after treatment often occur in these patients, leading to poor prognosis[@b2]. Therefore, it is important to identify novel biomarkers associated with tumor progression[@b3].

Currently, endoscopic examination of the nasopharynx and histological examination of tissues are usually used to diagnose NPC. However, clinical biopsies of the nasopharynx are highly invasive and inconvenient, and repeated examinations are not clinically practical. Radiologic examinations are useful for determining the extent of the disease. However, these imaging techniques are generally costly and time-consuming. Antibodies against EBV antigens are frequently used for NPC screening because serologic assays are relatively inexpensive and noninvasive. However, the results of these serologic tests alone are insufficient to accurately diagnose NPC[@b4]. At the same time, differences in clinical outcomes have been reported in patients who are at the same stage and receive similar treatment regimens [@b5]. These findings suggest that the present staging system is inadequate for prognosis. Driven by this demand, various biomarkers associated with prognosis have been reported. Nevertheless, new diagnostic and prognostic biomarkers are still needed for NPC.

In general, biomarkers that are ideal for clinical application should be easily accessible. Therefore, biomarkers that can be sampled from body fluids such as plasma and serum are particularly desirable[@b6]. MicroRNAs (miRNAs) are ideal biomarkers because they are commonly present in blood-based samples[@b7],[@b8]. Some human tumors have been successfully identified through miRNA expression profiling[@b9],[@b10]. miRNAs are non-coding RNA molecules that are approximately 22 nucleotides in length and regulate a variety of cellular processes including cell proliferation, differentiation, and apoptosis. miRNAs play an important role in carcinogenesis through either oncogenic or tumor-suppressive functions[@b11]. The extensive miRNA profile has become an important tool for developing valuable biomarkers and elucidating their roles in tumorigenesis. In NPC, human miRNA profiles from clinical biopsies have been examined[@b12]--[@b15]. Based on tissue miRNA profiling, some aberrant miRNAs were discovered, and their roles in NPC were further investigated[@b16]--[@b18]. Although plasma and serum miRNA profiles have been extensively studied in other cancers[@b19]--[@b27], few studies have examined human miRNA profiles in plasma from NPC patients.

Herein, we aimed to examine the miRNA expression profiles in plasma samples from NPC patients to reveal potential biomarkers and further explore the malignancy of NPC cell lines and clinical tissues.

Materials and Methods {#s2}
=====================

Study populations {#s2a}
-----------------

We collected plasma and tissue samples from participants who underwent nasopharyngeal biopsy at the Sun Yat-sen University Cancer Center (SYSUCC). The plasma samples were collected from April 2010 to August 2010, and the tissue samples were collected from April 2002 to August 2010. Most of the participants had biopsy-proven NPC, whereas some had chronic nasopharyngitis and could therefore serve as clinical controls. The patients were newly diagnosed with NPC and had no history of cancer or cancer treatment. Finally, plasma samples from 82 NPC patients and 50 controls were collected. According to their chronologic order, they were divided into a microarray cohort (*n* = 50) and a validation cohort (*n* = 82). Moreover, biopsy tissues were collected from 54 NPC patients and 22 controls. This study was approved by the Human Ethics Committee of SYSUCC, and all participants provided informed consent.

Cell lines {#s2b}
----------

Three NPC cell lines (CNE1, CNE2, and HNE1) and one immortalized nasopharyngeal epithelial cell line (NP69) were provided by professor Mu-Seng Zeng, Department of Experimental Research, SYSUCC. NP69 was cultured in defined, serum-free keratinocyte medium (Invitrogen, Carlsbad, CA, USA) as described previously[@b28], and the other three cell lines were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum. The cells were maintained in a humidified incubator at 37°C with 5% CO~2~.

Plasma preparation {#s2c}
------------------

For the plasma preparation, peripheral blood (3 mL) was drawn into EDTA tubes. Within 30 min, the tubes were centrifuged at 820 ×*g* for 10 min. Then, 1-mL aliquots of the plasma were transferred to 1.5-mL tubes and centrifuged at 16,000 ×*g* for an additional 10 min to remove any remaining cellular debris. Subsequently, the supernatants were transferred to fresh tubes and immediately stored at --80°C.

RNA extraction {#s2d}
--------------

RNA was isolated from 400 µL of plasma using the mirVana PARIS miRNA Isolation Kit (Ambion, Austin, TX, USA) according to the manufacturer\'s instructions. Total RNA from cells and clinical tissues was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. The RNA concentration was quantified using a NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Waltham, MA, USA).

MicroRNA profiling using microarrays {#s2e}
------------------------------------

Microarrays from Agilent Technologies (Santa Clara, CA, USA) were used to profile human miRNAs and identify differentially expressed miRNAs using plasma samples from 31 NPC patients and 19 controls (microarray cohort). The details of the microarray hybridizations were described previously[@b23]. The raw miRNA data are available in Gene Expression Omnibus (GEO) as GSE43329. The raw signals obtained for single-color CY3 hybridization were normalized to a stable endogenous control, *miR-454*, which was chosen due to its low coefficient of variance (CV) and positive signal in the microarray. Then, log~10~ transformation was performed before data analysis.

Reverse transcription {#s2f}
---------------------

For all samples, total RNA (40 ng) was used for reverse transcription with a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer\'s protocol. Reverse transcription reactions were conducted with custom stem-loop primers (Applied Biosystems) that were specific to the corresponding mature sequence obtained from miRBase ([www.miRBase.org](www.miRBase.org)).

Quantitative polymerase chain reaction (Q-PCR) {#s2g}
----------------------------------------------

To test the candidate miRNAs discovered using the microarrays, Q-PCR was performed using TaqMan microRNA assays (Applied Biosystems). *miR-454*, which was the control used in the microarray, was selected as the endogenous control in the plasma, whereas *RNU6B* was used as the endogenous control in the NPC cell lines and tissues. All cycle threshold (Ct) values were determined in real time with the ABI 7900HT system and analyzed with SDS Relative Quantification Software 2.2.3 (Applied Biosystems). All reactions were performed in triplicate.

Statistical analyses {#s2h}
--------------------

SPSS 16.0 software was used to perform the statistical analyses. All *P* values were two-sided, and values less than 0.05 were considered significant. The relative expression of the miRNAs as determined using Q-PCR was analyzed using the 2^−ΔΔCt^ method. The area under the receiver operating characteristic (ROC) curve (AUC) was used as an accuracy index for evaluating the diagnostic performance of the selected miRNA combinations.

Results {#s3}
=======

Characteristics of the study population {#s3a}
---------------------------------------

A total of 132 plasma samples and 76 biopsy tissues were collected in this study. The characteristics of the study population are shown in **[Table 1](#cjc-33-07-330-t01){ref-type="table"}**. The cancer stage is usually evaluated by clinical doctors based on the comprehensive results of magnetic resonance imaging (MRI), histopathologic type, and clinical symptoms. Although some patients at our cancer center had biopsy-proven NPC, they were moved to other hospitals for further diagnosis and treatment; thus, examinations such as MRI for these patients were not conducted at our cancer center. Therefore, in our study, the cancer stage information associated with 32 plasma samples and 13 clinical tissue samples was lost, and only histopathologic information was obtained.

###### Characteristics of the study population

  Variable                 Plasma sample group   Tissue sample group                         
  ----------------------- --------------------- --------------------- ------- ------- ------ ------
  Age (years)                                                                                
   Mean                           46.23                 43.26          46.72   42.19   44.5   40.4
   Median                          45                    41             47      40      45     40
   Maximum                         62                    59             73      73      63     64
   Minimum                         27                    28             14      14      18     18
  Gender (cases)                                                                             
   Male                            21                    12             46      19      39     9
   Female                          10                     7              5      12      15     13
  Cancer stage (cases)                                                                       
   Stage I                          0                    N/A             0      N/A     1     N/A
   Stage II                         2                    N/A             8      N/A     8     N/A
   Stage III                       10                    N/A            16      N/A     25    N/A
   Stage IV                         7                    N/A             7      N/A     7     N/A
   Unknown                         12                    N/A            20      N/A     13    N/A
  VCA-IgA titer (cases)                                                                      
   Negative                         0                    15              3      14      0      16
   1:10 - 1:20                      0                     4              3      17      2      6
   1:40 - 1:80                      3                     0             12       0      12     0
   1:160                           28                     0             33       0      40     0
  EA-IgA titer (cases)                                                                       
   Negative                         2                    19             19      31      10     22
   1:10 - 1:20                     11                     0             22       0      30     0
   1:40 - 1:80                     18                     0             10       0      14     0
   1:160                            0                     0              0       0      0      0

NPC, nasopharyngeal carcinoma; VCA, Epstein-Barr virus (EBV) viral capsid antigen; EA, EBV early antigen; N/A, not applicable.

###### A total of 39 altered microRNAs were found using 50 microarrays

  MicroRNA                  Mean signal intensity   Fold change   *P*   
  ------------------------ ----------------------- ------------- ------ ----------
  *hsa*-*miR*-*548q*               496.31             158.39      3.13   \< 0.001
  *hsa*-*miR*-*483*-*5p*           615.53             238.09      2.59    0.002
  *hsa*-*miR*-*122*                817.00             330.46      2.47    0.012
  *hsa*-*miR*-*630*                292.53             122.13      2.40    0.001
  *hsa*-*miR*-*135a\**             252.26             106.13      2.38    0.001
  *hsa*-*miR*-*572*                692.77             297.65      2.33    0.006
  *hsa*-*miR*-*940*                586.09             256.28      2.29    0.001
  *hsa*-*miR*-*29c*                365.32             164.43      2.22    0.005
  *hsa*-*miR*-*22*                2,963.42           1,430.17     2.07    0.035
  *hsa*-*miR*-*1915*              1,671.75            806.96      2.07    0.005
  *hsa*-*miR*-*762*               2,212.08           1,089.96     2.03    0.048
  *hsa*-*miR*-*1290*               253.28             124.91      2.03    0.001
  *hsa*-*miR*-*765*                261.43             129.60      2.02    0.001
  *hsa*-*miR*-*92a*               2,196.96           1,097.13     2.00    0.050
  *hsa*-*miR*-*486*-*5p*          4,726.64           2,438.34     1.94    0.040
  *hsa*-*miR*-*638*               11,792.79          6,090.35     1.94    0.010
  *hsa*-*miR*-*140*-*3p*           276.09             143.45      1.92    0.009
  *hsa*-*miR*-*1246*              1,151.10            606.00      1.90    0.020
  *hsa*-*miR*-*15b*                284.72             153.94      1.85    0.013
  *hsa*-*miR*-*30d*                211.89             115.65      1.93    0.018
  *hsa*-*miR*-*19a*                264.51             149.60      1.77    0.035
  *hsa*-*miR*-*126*                242.84             141.28      1.72    0.022
  *hsa*-*miR*-*20a*                301.29             175.73      1.71    0.042
  *hsa*-*miR*-*185*                175.68             105.20      1.67    0.004
  *hsa*-*miR*-*93*                 160.50              99.09      1.62    0.002
  *hsa*-*miR*-*101*                161.92             104.49      1.55    0.006
  *hsa*-*miR*-*187\**              118.51              78.63      1.51    0.041
  *hsa*-*miR*-*498*                158.63             109.54      1.45    0.007
  *hsa*-*miR*-*1234*               181.41             125.49      1.45    0.042
  *hsa*-*miR*-*1975*               137.34              98.82      1.39    0.012
  *hsa*-*miR*-*575*                136.09              98.68      1.38    0.020
  *hsa*-*miR*-*17*                 123.00              89.62      1.37    0.022
  *hsa*-*miR*-*130a*               147.93             108.78      1.36    0.038
  *hsa*-*miR*-*363*                137.47             104.69      1.31    0.048
  *hsa*-*miR*-*301a*               127.85              99.89      1.28    0.009
  *hsa*-*miR*-*192*                120.74              98.97      1.22    0.018
  *hsa*-*miR*-*338*-*3p*           115.82              99.60      1.16    0.021
  *hsa*-*miR*-*1277*               214.86             309.95      0.69    0.039
  *hsa*-*miR*-*584*                115.88             199.49      0.58    0.040

Candidate biomarkers discovered using 50 microarrays {#s3b}
----------------------------------------------------

By comparing miRNA expression profiles using samples from the microarray cohort, 39 miRNAs with significantly different expression levels were identified. A total of 37 miRNAs were up-regulated in the NPC patients compared with the controls, whereas 2 miRNAs were down-regulated. There were 14 miRNAs with a fold change \> 2 and 11 miRNAs with *P* \< 0.005. Overall, 9 miRNAs (*miR-548q*, *miR-1290*, *miR-630*, *miR-765*, *miR-135a\**, *miR-940*, *miR-483-5p*, *miR-29c*, and *miR-1915*) with both a fold change \> 2 and *P* \< 0.005 had great potential for use in NPC diagnosis (**[Table 2](#cjc-33-07-330-t02){ref-type="table"}**).

*miR*-*548q* and *miR*-*483*-*5p* were validated in 132 samples using Q-PCR {#s3c}
---------------------------------------------------------------------------

*miR-548q* and *miR-483-5p* were the top two miRNAs with a fold change \>2 and *P* value \< 0.005. Therefore, they were selected first for validation using Q-PCR. The validations were conducted in the microarray cohort and the validation cohort. Increased expression of *miR-548q* and *miR-483-5p* was observed in the microarray cohort (*P* = 0.046 for *miR-548q*; *P* = 0.059 for *miR-483-5p*) and the validation cohort (*P* = 0.058 for *miR-548q*; *P* = 0.050 for *miR-483-5p*). The differences in *miR-548q* in the validation cohort and *miR-483-5p* in the microarray cohort were not quite significant, most likely due to the sample size. Finally, the increased expression levels of *miR-548q* (fold change = 2.01, *P* = 0.011) and miR-483-5p (fold change = 1.59, *P* = 0.023) were validated by combining the two cohorts (**[Figure 1](#cjc-33-07-330-g001){ref-type="fig"}**).

High expression of *miR*-*548q* and *miR*-*483*-*5p* was further validated in NPC cell lines and biopsy tissues {#s3d}
---------------------------------------------------------------------------------------------------------------

Compared with its expression level in NP69 cells, the expression level of *miR-548q* was significantly increased in the NPC cell lines, including HNE1 (fold change = 2.51, *P* \< 0.001), CNE2 (fold change = 2.34, *P* \< 0.001), and CNE1 (fold change = 2.13, *P* \< 0.001) (**[Figure 2A](#cjc-33-07-330-g002){ref-type="fig"}**). Similarly, increased expression of *miR-483-5p* was also observed in HNE1 (fold change = 3.94, *P* = 0.03), CNE2 (fold change = 3.55, *P* = 0.01), and CNE1 cells (fold change = 24.87, *P* \< 0.001) (**[Figure 2B](#cjc-33-07-330-g002){ref-type="fig"}**).

Consistent with the trend observed in plasma and cell lines, increased expression of *miR-548q* (fold change = 3.56, *P* = 0.003) (**[Figure 2C](#cjc-33-07-330-g002){ref-type="fig"}**) and *miR-483-5p* (fold change = 11.18, *P* \< 0.001) (**[Figure 2D](#cjc-33-07-330-g002){ref-type="fig"}**) was also found in NPC biopsy tissues compared to controls.

*miR*-*548q* and *miR*-*483*-*5p* contributed to diagnosis and prognosis {#s3e}
------------------------------------------------------------------------

In plasma samples, we determined a sensitivity of 62.2% and a specificity of 60.0% using *miR-548q* (AUC, 0.631) in ROC analysis. Using *miR-483-5p* (AUC, 0.600), we observed a sensitivity of 62.2% and a specificity of 58.0% (data not shown). The combination of *miR-548q* and *miR-483-5p* produced an increased AUC of 0.737, with 67.1% sensitivity and 68.0% specificity, indicating an additive effect in the diagnostic value of these 2 miRNAs (**[Figure 3A](#cjc-33-07-330-g003){ref-type="fig"}**). In biopsy tissue samples from NPC patients, the expression levels of *miR-548q* and *miR-483-5p* were classified into low and high groups according to their medians. A total of 17 NPC patients died; of these 17 patients, 12 (70.6%) had an *miR-548q* expression level higher than its median and 11 (64.7%) had an *miR-483-5p* expression level higher than its median. These results indicate that high expression of *miR-548q* and *miR-483-5p* might contribute to poor prognosis (**[Figure 3B](#cjc-33-07-330-g003){ref-type="fig"}**).

![Plasma *miR*-*548q* and *miR*-*483*-*5p* expression levels.\
Increased expression levels of *miR*-*548q* (A) and *miR*-*483*-*5p* (B) were validated in the microarray cohort (left), the validation cohort (middle), and the combined cohort (right).](cjc-33-07-330-g001){#cjc-33-07-330-g001}

![The expression levels of *miR*-*548q* and *miR*-*483*-*5p* in cell lines and biopsy tissues.\
Increased expression levels of *miR*-*548q* and *miR*-*483*-*5p* were validated in cell lines (A, B) and biopsy tissues (C, D) from nasopharyngeal carcinoma (NPC) patients. The *P* values were calculated using an independent two-tailed *t*-test (\**P* \< 0.05, \*\**P* \< 0.005; *n* = 6 per group).](cjc-33-07-330-g002){#cjc-33-07-330-g002}

![*miR*-*548q* and *miR*-*483*-*5p* contributed to diagnosis and prognosis.\
A, the combination of *miR*-*548q* and *miR*-*483*-*5p* produced an area under the receiver operating characteristic (ROC) curve (AUC) of 0.737, with 67.1% sensitivity and 68.0% specificity. B, based on the analysis of the tissue samples from NPC patients, most of the patients who died exhibited high expression (≥ median) of *miR*-*548q* and *miR*-*483*-*5p*.](cjc-33-07-330-g003){#cjc-33-07-330-g003}

Discussion {#s4}
==========

In this study, a total of 39 altered miRNAs were found using 50 microarrays containing 887 miRNAs. The increased expression levels of *miR-548q* and *miR-483-5p* were further validated by Q-PCR in plasma, cell lines, and biopsy tissues from NPC patients. These consistent results pave the way for further exploration of the roles of these miRNAs in tumorigenesis.

Recently, efforts have been made to examine human miRNA profiles in the serum of NPC patients. In 2012, miRNA profiling of serum samples pooled from 20 NPC patients or 20 controls was conducted to explore the diagnostic value of serum miRNAs using a TaqMan Low-Density Array, and *miR-17*, *miR-20a*, *miR-29c*, and *miR-223* were found to be differently expressed[@b29]. In 2013, miRNA profiling of serum samples from 8 NPC patients with a long survival and 8 patients with a shorter survival was conducted to explore the prognostic value of serum miRNAs, and *miR-22*, *miR-572*, *miR-638*, and *miR-1234* were found to be altered between these two groups[@b30]. In our study, 50 microarrays of plasma samples from 31 NPC patients and 19 controls were analyzed, and a comprehensive miRNA profile was obtained. A large sample size may aid in discovering more potential biomarkers. In fact, all the miRNAs reported in serum except *miR-223* were discovered in our microarray (**[Table 2](#cjc-33-07-330-t02){ref-type="table"}**).

*miR-548q* was initially identified in epithelial ovarian cancer samples through next-generation sequencing[@b31]. To date, no reports have described this miRNA in other tumors. *miR-483-5p* was initially identified as a predictor of poor prognosis in adrenocortical cancer in 2009[@b32]. Later, *miR-483-5p* was shown to serve as a biomarker of malignancy that could be used to accurately categorize adrenocortical tumors as benign or malignant [@b33]. In the current study, the expression levels of *miR-548q* and *miR-483-5p* were validated to be higher in plasma from NPC patients than in plasma from controls (**[Figure 1](#cjc-33-07-330-g001){ref-type="fig"}**).

Interestingly, higher expression levels of *miR-548q* and *miR-483-5p* were found in NPC cell lines (CNE1, CNE2, and HNE1) compared to an immortalized nasopharyngeal epithelial cell line (NP69) and clinical biopsy tissues (**[Figure 2](#cjc-33-07-330-g002){ref-type="fig"}**), suggesting that these miRNAs might be involved in NPC development. Because the numbers of males and females in the NPC patient and control groups were not well balanced (**[Table 1](#cjc-33-07-330-t01){ref-type="table"}**), the difference between males and females in each group was compared using plasma samples and biopsy tissue samples. No significant differences were observed between genders; however, nearly significant and significant differences were observed between controls and NPC patients of the same gender. These results further demonstrated that the differences observed were due to tumorigenesis.

Thus far, some miRNAs have been found to be altered in cells or tissues after conducting tissue miRNA microarray experiments[@b12]--[@b15]. Further, the roles of some miRNAs in tumorigenesis have been explored[@b16]--[@b18],[@b34]--[@b40]. However, the examination of miRNA expression profiles in tissue samples is inconvenient, and these profiles cannot be used to screen high-risk populations. By contrast, plasma microRNA expression profiles provide valuable biomarkers for the diagnosis of NPC. Currently, few miRNAs are known to be altered in both plasma and clinical tissues. With the development of personalized therapy, the combination of diagnostic application and functional regulation may be focused on one biomarker. Given the overexpression of *miR-548q* and *miR-483-5p* in both plasma and tissue, we also examined the potential target pathways and typical genes using bioinformatic tools. For example, genes involved in ubiquitin-mediated proteolysis (*VHL*, *UBE3A*, and *UBE3B*) were targeted by *miR-483-5p*, and genes involved in apoptosis (*BCL2L2*, *BCL2L11*) were targeted by *miR-548q*. Interestingly, genes involved in the cell cycle (*CDKN2A* and *CDKN2B* by *miR-548q*; *CDKN1A* by *miR-483-5p*) and p53 signaling (*HIPK2* and *TP53INP2* by *miR-548q*; *HIPK2* by *miR-483-5p*) were targeted by both *miR-548q* and *miR-483-5p* (data not shown). Despite the limitations of this study, our results provide preliminary insight into the mechanisms underlying miRNA-related tumorigenesis. Based on the positive results of this preliminary study, further functional investigation of *miR-548q* and *miR-483-5p* should be conducted in the future.

Based on the results of our 50 microarrays, we found that 39 miRNAs exhibited significant expression differences (**[Table 2](#cjc-33-07-330-t02){ref-type="table"}**). In the first phase of the study, only two potential biomarkers (*miR-548q* and *miR-483-5p*) were selected for validation based on their fold change and *P* value (**[Figure 1](#cjc-33-07-330-g001){ref-type="fig"}**). Our data suggested that either biomarker alone or in combination may not provide sufficient predictive accuracy (**[Figure 3A](#cjc-33-07-330-g003){ref-type="fig"}**). However, a miRNA panel has been reported to greatly improve the performance of a single biomarker. For example, a panel of 7 miRNAs was successfully constructed to diagnose hepatitis B virus-related hepatocellular carcinoma[@b23]. In addition, a combination of 10 miRNAs was used as a novel biomarker for non-small cell lung cancer diagnosis[@b24]. Therefore, other miRNAs with significant differences should be validated, and a better predictive panel may be constructed in the future. Due to the loss of patient information and limitation of sample size, the prognostic value of *miR-548q* and *miR-483-5p* could not be accurately evaluated in this study. Only 17 patients with NPC died, and most of the patients who died had high expression levels of *miR-548q* and *miR-483-5p* (**[Figure 3B](#cjc-33-07-330-g003){ref-type="fig"}**). Our preliminary results indicated that *miR-548q* and *miR-483-5p* might play an important role in tumorigenesis and have an effect on prognosis. However, further study is needed to fully understand their contribution to prognosis.

In conclusion, in this study, we found that *miR-548q* and *miR-483-5p* are potential biomarkers of NPC. Specific miRNAs are consistently found in cells, clinical tissues, and the blood circulation; thus, their role in tumorigenesis can be easily explored. The plasma miRNA expression profiles were important resources for revealing biomarkers of malignancy.
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